Current Status
Not Enrolled
Price
Free
Get Started
Course
Slides
Transcripts

Current and Emerging ERTs/SRTs

To obtain CME/CE credit, you must LOG-IN and ENROLL (click orange button at top of page)

Lysosomal & Rare Disorders Research & Treatment Center

Current and Emerging ERTs/SRTs

September 30, 2022 – September 30, 2023

Estimated time to complete: 1.0 hours

Activity Description

This CME activity highlights how enzyme replacement therapies (ERTs) and substrate reduction therapies (SRTs) for lysosomal storage disorders have transformed, and will continue to transform, the treatment landscape for these rare conditions.

Continuing Education Information

This continuing education activity is provided through collaboration between Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare, and AffinityCE. This activity provides continuing education credit for Physicians, Physician Assistants, Nurse Practitioners, Nurses, Genetic Counselors as well as a statement of participation for other participants.

Faculty

Ozlem Goker-Alpan, MD
Co-founder and President
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

Neal J Weinreb, MD, FACP
Voluntary Associate Professor of Human Genetics
University of Miami Miller School of Medicine

Learning Outcomes

At the end of this activity, participants should be able to:

  • Describe how ERTs/SRTs have transformed the LSD population
  • Describe the new research underway to improve safety and efficacy of ERTs/SRTs
  • Describe how ERTs/SRTs are addressing the problem of the blood brain barrier

Disclosures

AffinityCE, LDRTC, and CheckRare CE staff, as well as planning and review committees, have no financial interests to disclose and do not recommend the use of products outside of the FDA approved labelling.

Faculty Educators

Dr. Ozlem Goker-Alpan is a consultant, a principal investigator and /or on the speaker bureau, or has received grant support from the following pharmaceutical companies: Actelion, Amicus Therapeutics, Genzyme Inc., Shire HGT, Pfizer/Protalix

Dr. Weinreb is on the Advisory Board and a Consultant and Speaker for Sanofi; Advisory Board and Consultant for Pfizer; Advisory Board for Avrobio and Takeda.

Any conflict of interest for Drs. Goker-Alpan and Weinreb were resolved through peer review of content by a non-conflicted reviewer.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 1 hour of continuing nursing education credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselors

Category 2 CEU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. This activity meets Category 2 CEUs requirements of the National Society of Genetic Counselors (NCGC).

Other Professionals

All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational Support for this activity was provided by Takeda, Sanofi, and Chiesi.

Participation Costs

There is no cost to participate in these CE sessions.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Send customer support requests to cds_support+ldrtc@affinityced.com.

Current and Emerging ERTs/SRTs

Slides

LDRTC2022 Current and Emerging ERTs-SRTs-introduction

Introduction

 

LDRTC2022 Current and Emerging ERTs-SRTs-slides-weinreb

Dr Weinreb's slides

Current and Emerging ERTs/SRTs

Transcripts